相关实验视频

Updated: Jul 13, 2025

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

在先进的软组织肉瘤中,随机化第二阶段临床试验使用奥拉图马布与吉米西塔和多塞塔结合使用

Steven Attia¹, Victor Villalobos², Nadia Hindi^3,4,5

¹Mayo Clinic, Jacksonville, FL 32224, USA.

|October 14, 2023

概括

广告2试验研究了将olaratumab添加到gemcitabine和docetaxel中,用于高级软组织肉瘤. 这种组合并没有显著改善患者队列中的整体存活率.

科学领域:

在瘤学瘤学.
临床试验临床试验
软组织肉瘤 (软组织肉瘤)

背景情况:

晚期软组织肉瘤 (STSs) 预后不好,尽管有有效的治疗方法,如gemcitabine加 docetaxel.
对于改善晚期STS患者的长期结果,急需新型疗法.
广告 2 试验的目的是评估 olaratumab 与吉姆西塔和多塞塔结合使用.

研究的目的:

探索添加olaratumab与gemcitabine和docetaxel在患有晚期STS的患者中的疗效和安全性.
为了评估总体存活率 (OS) 作为 olaratumab-naïve 患者的主要终点.
评估包括OS在 olaratumab 预治疗患者中的二次终点,安全性和患者报告的结果.

主要方法:

第二阶段随机试验招募了局部晚期/转移性STS不能切除的成年人和有限的先前治疗.
患者被随机分为两个队列: olaratumab-naïve和 olaratumab-预治疗.
治疗涉及olaratumab,gemcitabine和docetaxel的循环,OS作为olaratumab-naïve队列的主要终点.

主要成果:

在试验和对照组之间,无论是在 olaratumab-naïve (HR=0.95,p=0.78) 或 olaratumab-pretreated (HR=0.67,p=0.15) 队列中,在总生存期中没有观察到统计学上显著的差异.
中位数的生存期为16.8个月,相比之下18.0个月的 olaratumab-naïve队列和19.8个月相比之下17.3个月的 olaratumab-pretreated队列.
在所有治疗臂中,安全概况是可以管理的,没有发现新的安全信号.

结论:

将olaratumab添加到gemcitabine和docetaxel并没有导致高级STS患者的整体存活率在统计学上显著改善.
基于未达到主要终点,其他结果不被认为具有统计学意义.
组合疗法显示出可管理的安全性概况,但没有达到主要的疗效目标.

关键词:

多塞塔克塞尔 (Docetaxel) 是一种药物.这种药物是 gemcitabine.雷奥米奥萨科马 (leiomyosarcoma) 是一种癌症.他们将会转移到其他地方.总体存活率总体存活率没有进展的生存率.软组织肉瘤 (软组织肉瘤)

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...